lenticrisprv2 Search Results


lenticrisprv2 plasmids  (Addgene inc)
92
Addgene inc lenticrisprv2 plasmids

Lenticrisprv2 Plasmids, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticrisprv2/sgCtr-+LentiCRISPRv2+(Plasmid+%23107402)/pmc11513839-156-0-5
Average 92 stars, based on 1 article reviews
lenticrisprv2 plasmids - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
paper n a lenticrisprv2 puro addgene  (Addgene inc)
98
Addgene inc paper n a lenticrisprv2 puro addgene

Paper N A Lenticrisprv2 Puro Addgene, supplied by Addgene inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticrisprv2/lentiCRISPRv2+puro+(Plasmid+%2398290)/pm41932308-260-38-42
Average 98 stars, based on 1 article reviews
paper n a lenticrisprv2 puro addgene - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier
lenticrisprv2 hygro  (Addgene inc)
94
Addgene inc lenticrisprv2 hygro

Lenticrisprv2 Hygro, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticrisprv2/lentiCRISPRv2+hygro+(Plasmid+%2398291)/bio_rxiv__2024__10__10__617692-310-18-19
Average 94 stars, based on 1 article reviews
lenticrisprv2 hygro - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
agata smogorzewska  (Addgene inc)
95
Addgene inc agata smogorzewska

Agata Smogorzewska, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticrisprv2/LentiCRISPRv2-mCherry+(Plasmid+%2399154)/10__1172_slash_jci145142-183-17-19
Average 95 stars, based on 1 article reviews
agata smogorzewska - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
lenticrispr v2 blast  (Addgene inc)
96
Addgene inc lenticrispr v2 blast

Lenticrispr V2 Blast, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticrisprv2/lentiCRISPRv2+blast+(Plasmid+%2398293)/pmc12627610-291-37-40
Average 96 stars, based on 1 article reviews
lenticrispr v2 blast - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
plenticrisprv2 backbones carrying neomycin  (Addgene inc)
96
Addgene inc plenticrisprv2 backbones carrying neomycin

Plenticrisprv2 Backbones Carrying Neomycin, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticrisprv2/lentiCRISPRv2+neo+(Plasmid+%2398292)/bio_rxiv__64898__2026__03__16__712171-238-10-14
Average 96 stars, based on 1 article reviews
plenticrisprv2 backbones carrying neomycin - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
atg5  (Addgene inc)
95
Addgene inc atg5
( A ) Basal level LC3B-II observation densities show a near-zero distribution for both groups, while the COPD group exhibited a significant reduction in LC3B-II accumulation with chloroquine (QC), vs the controls. ( B ) A representative blot (n=6 in total) comparing no-treatment and CQ outcomes for LC3B-I/II and Actin-β (ACTB). C ). Measures of autophagic flux (ΔLC3B-II) showed a significant reduction in autophagic competency for the COPD group. ( D ) The LC3B-I/II antibody was validated using protein isolated from 16HBE14o-cells transduced with a CRISPR <t>ATG5</t> KO construct. As expected, the depletion of ATG5 caused a large reduction in the LC3B-II signal (the lipidated form of LC3B-I), and substantial increases in the LC3B-I and p62/Sequestosome-1 (SQSTM1) signals. Pink-purple color within the LC3B-I and Sequestosome-1/p62 blots indicate signal saturation beyond the linear range determined for these proteins. Outcomes for LC3B-II were normalized to the Actin-β signal. Control, n=16 and COPD, n= 22. “**” denoted P < 0 . 01. Outcomes for the violin graphs were from non-parametric analyses; Wilcoxon matched pairs rank were used when comparing no-treatment and CQ, and Kruskall-Wallis rank test for comparisons between control vs COPD. Violin graphs boxplots show ± standard error and whiskers denote ± 95% CI .
Atg5, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticrisprv2/LentiCRISPRv2-ATG5+(Plasmid+%2399573)/bio_rxiv__2024__04__27__591479-53-17-30
Average 95 stars, based on 1 article reviews
atg5 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
lenticrisprv2 beclin1 plasmid  (Addgene inc)
93
Addgene inc lenticrisprv2 beclin1 plasmid
( A ) Basal level LC3B-II observation densities show a near-zero distribution for both groups, while the COPD group exhibited a significant reduction in LC3B-II accumulation with chloroquine (QC), vs the controls. ( B ) A representative blot (n=6 in total) comparing no-treatment and CQ outcomes for LC3B-I/II and Actin-β (ACTB). C ). Measures of autophagic flux (ΔLC3B-II) showed a significant reduction in autophagic competency for the COPD group. ( D ) The LC3B-I/II antibody was validated using protein isolated from 16HBE14o-cells transduced with a CRISPR <t>ATG5</t> KO construct. As expected, the depletion of ATG5 caused a large reduction in the LC3B-II signal (the lipidated form of LC3B-I), and substantial increases in the LC3B-I and p62/Sequestosome-1 (SQSTM1) signals. Pink-purple color within the LC3B-I and Sequestosome-1/p62 blots indicate signal saturation beyond the linear range determined for these proteins. Outcomes for LC3B-II were normalized to the Actin-β signal. Control, n=16 and COPD, n= 22. “**” denoted P < 0 . 01. Outcomes for the violin graphs were from non-parametric analyses; Wilcoxon matched pairs rank were used when comparing no-treatment and CQ, and Kruskall-Wallis rank test for comparisons between control vs COPD. Violin graphs boxplots show ± standard error and whiskers denote ± 95% CI .
Lenticrisprv2 Beclin1 Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticrisprv2/LentiCRISPRv2-Beclin1+(Plasmid+%2399574)/pmc07138813-56-9-14
Average 93 stars, based on 1 article reviews
lenticrisprv2 beclin1 plasmid - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
lenticrisprv2 grna plasmid  (Addgene inc)
93
Addgene inc lenticrisprv2 grna plasmid
( A ) Basal level LC3B-II observation densities show a near-zero distribution for both groups, while the COPD group exhibited a significant reduction in LC3B-II accumulation with chloroquine (QC), vs the controls. ( B ) A representative blot (n=6 in total) comparing no-treatment and CQ outcomes for LC3B-I/II and Actin-β (ACTB). C ). Measures of autophagic flux (ΔLC3B-II) showed a significant reduction in autophagic competency for the COPD group. ( D ) The LC3B-I/II antibody was validated using protein isolated from 16HBE14o-cells transduced with a CRISPR <t>ATG5</t> KO construct. As expected, the depletion of ATG5 caused a large reduction in the LC3B-II signal (the lipidated form of LC3B-I), and substantial increases in the LC3B-I and p62/Sequestosome-1 (SQSTM1) signals. Pink-purple color within the LC3B-I and Sequestosome-1/p62 blots indicate signal saturation beyond the linear range determined for these proteins. Outcomes for LC3B-II were normalized to the Actin-β signal. Control, n=16 and COPD, n= 22. “**” denoted P < 0 . 01. Outcomes for the violin graphs were from non-parametric analyses; Wilcoxon matched pairs rank were used when comparing no-treatment and CQ, and Kruskall-Wallis rank test for comparisons between control vs COPD. Violin graphs boxplots show ± standard error and whiskers denote ± 95% CI .
Lenticrisprv2 Grna Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticrisprv2/lentiCRISPRv2-TTF-1-gRNA+(Plasmid+%23101857)/pm40053593-290-25-33
Average 93 stars, based on 1 article reviews
lenticrisprv2 grna plasmid - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
plenticrisprv2 msting grna 1  (Addgene inc)
93
Addgene inc plenticrisprv2 msting grna 1
( A ) Basal level LC3B-II observation densities show a near-zero distribution for both groups, while the COPD group exhibited a significant reduction in LC3B-II accumulation with chloroquine (QC), vs the controls. ( B ) A representative blot (n=6 in total) comparing no-treatment and CQ outcomes for LC3B-I/II and Actin-β (ACTB). C ). Measures of autophagic flux (ΔLC3B-II) showed a significant reduction in autophagic competency for the COPD group. ( D ) The LC3B-I/II antibody was validated using protein isolated from 16HBE14o-cells transduced with a CRISPR <t>ATG5</t> KO construct. As expected, the depletion of ATG5 caused a large reduction in the LC3B-II signal (the lipidated form of LC3B-I), and substantial increases in the LC3B-I and p62/Sequestosome-1 (SQSTM1) signals. Pink-purple color within the LC3B-I and Sequestosome-1/p62 blots indicate signal saturation beyond the linear range determined for these proteins. Outcomes for LC3B-II were normalized to the Actin-β signal. Control, n=16 and COPD, n= 22. “**” denoted P < 0 . 01. Outcomes for the violin graphs were from non-parametric analyses; Wilcoxon matched pairs rank were used when comparing no-treatment and CQ, and Kruskall-Wallis rank test for comparisons between control vs COPD. Violin graphs boxplots show ± standard error and whiskers denote ± 95% CI .
Plenticrisprv2 Msting Grna 1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticrisprv2/LentiCRISPRv2+mSTING+(Plasmid+%23129581)/pmc12904717-294-22-25
Average 93 stars, based on 1 article reviews
plenticrisprv2 msting grna 1 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
lenticrisprv2 plasmid 2  (Addgene inc)
86
Addgene inc lenticrisprv2 plasmid 2
( A ) Basal level LC3B-II observation densities show a near-zero distribution for both groups, while the COPD group exhibited a significant reduction in LC3B-II accumulation with chloroquine (QC), vs the controls. ( B ) A representative blot (n=6 in total) comparing no-treatment and CQ outcomes for LC3B-I/II and Actin-β (ACTB). C ). Measures of autophagic flux (ΔLC3B-II) showed a significant reduction in autophagic competency for the COPD group. ( D ) The LC3B-I/II antibody was validated using protein isolated from 16HBE14o-cells transduced with a CRISPR <t>ATG5</t> KO construct. As expected, the depletion of ATG5 caused a large reduction in the LC3B-II signal (the lipidated form of LC3B-I), and substantial increases in the LC3B-I and p62/Sequestosome-1 (SQSTM1) signals. Pink-purple color within the LC3B-I and Sequestosome-1/p62 blots indicate signal saturation beyond the linear range determined for these proteins. Outcomes for LC3B-II were normalized to the Actin-β signal. Control, n=16 and COPD, n= 22. “**” denoted P < 0 . 01. Outcomes for the violin graphs were from non-parametric analyses; Wilcoxon matched pairs rank were used when comparing no-treatment and CQ, and Kruskall-Wallis rank test for comparisons between control vs COPD. Violin graphs boxplots show ± standard error and whiskers denote ± 95% CI .
Lenticrisprv2 Plasmid 2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticrisprv2/sgPBRM1-2-+LentiCRISPRv2+(Plasmid+%23107404)/10__1165_slash_rcmb__2019___0266oc-250-45-48
Average 86 stars, based on 1 article reviews
lenticrisprv2 plasmid 2 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
lenticrisprv2 plasmid  (Addgene inc)
95
Addgene inc lenticrisprv2 plasmid
( A ) Basal level LC3B-II observation densities show a near-zero distribution for both groups, while the COPD group exhibited a significant reduction in LC3B-II accumulation with chloroquine (QC), vs the controls. ( B ) A representative blot (n=6 in total) comparing no-treatment and CQ outcomes for LC3B-I/II and Actin-β (ACTB). C ). Measures of autophagic flux (ΔLC3B-II) showed a significant reduction in autophagic competency for the COPD group. ( D ) The LC3B-I/II antibody was validated using protein isolated from 16HBE14o-cells transduced with a CRISPR <t>ATG5</t> KO construct. As expected, the depletion of ATG5 caused a large reduction in the LC3B-II signal (the lipidated form of LC3B-I), and substantial increases in the LC3B-I and p62/Sequestosome-1 (SQSTM1) signals. Pink-purple color within the LC3B-I and Sequestosome-1/p62 blots indicate signal saturation beyond the linear range determined for these proteins. Outcomes for LC3B-II were normalized to the Actin-β signal. Control, n=16 and COPD, n= 22. “**” denoted P < 0 . 01. Outcomes for the violin graphs were from non-parametric analyses; Wilcoxon matched pairs rank were used when comparing no-treatment and CQ, and Kruskall-Wallis rank test for comparisons between control vs COPD. Violin graphs boxplots show ± standard error and whiskers denote ± 95% CI .
Lenticrisprv2 Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lenticrisprv2/sgPBRM1-1-+LentiCRISPRv2+(Plasmid+%23107403)/pm35942101-296-6-28
Average 95 stars, based on 1 article reviews
lenticrisprv2 plasmid - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

Image Search Results


Journal: Cell Reports Medicine

Article Title: CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13

doi: 10.1016/j.xcrm.2024.101758

Figure Lengend Snippet:

Article Snippet: LentiCRISPRv2 Plasmids , – , Addgene Plasmid #107402.

Techniques: Virus, Recombinant, Plasmid Preparation, Blocking Assay, Lysis, Protease Inhibitor, Membrane, Transfection, SYBR Green Assay, Cell Viability Assay, Avidin-Biotin Assay, cDNA Synthesis, Software

( A ) Basal level LC3B-II observation densities show a near-zero distribution for both groups, while the COPD group exhibited a significant reduction in LC3B-II accumulation with chloroquine (QC), vs the controls. ( B ) A representative blot (n=6 in total) comparing no-treatment and CQ outcomes for LC3B-I/II and Actin-β (ACTB). C ). Measures of autophagic flux (ΔLC3B-II) showed a significant reduction in autophagic competency for the COPD group. ( D ) The LC3B-I/II antibody was validated using protein isolated from 16HBE14o-cells transduced with a CRISPR ATG5 KO construct. As expected, the depletion of ATG5 caused a large reduction in the LC3B-II signal (the lipidated form of LC3B-I), and substantial increases in the LC3B-I and p62/Sequestosome-1 (SQSTM1) signals. Pink-purple color within the LC3B-I and Sequestosome-1/p62 blots indicate signal saturation beyond the linear range determined for these proteins. Outcomes for LC3B-II were normalized to the Actin-β signal. Control, n=16 and COPD, n= 22. “**” denoted P < 0 . 01. Outcomes for the violin graphs were from non-parametric analyses; Wilcoxon matched pairs rank were used when comparing no-treatment and CQ, and Kruskall-Wallis rank test for comparisons between control vs COPD. Violin graphs boxplots show ± standard error and whiskers denote ± 95% CI .

Journal: bioRxiv

Article Title: Autophagy is suppressed in peripheral blood mononuclear cells during chronic obstructive pulmonary disease

doi: 10.1101/2024.04.27.591479

Figure Lengend Snippet: ( A ) Basal level LC3B-II observation densities show a near-zero distribution for both groups, while the COPD group exhibited a significant reduction in LC3B-II accumulation with chloroquine (QC), vs the controls. ( B ) A representative blot (n=6 in total) comparing no-treatment and CQ outcomes for LC3B-I/II and Actin-β (ACTB). C ). Measures of autophagic flux (ΔLC3B-II) showed a significant reduction in autophagic competency for the COPD group. ( D ) The LC3B-I/II antibody was validated using protein isolated from 16HBE14o-cells transduced with a CRISPR ATG5 KO construct. As expected, the depletion of ATG5 caused a large reduction in the LC3B-II signal (the lipidated form of LC3B-I), and substantial increases in the LC3B-I and p62/Sequestosome-1 (SQSTM1) signals. Pink-purple color within the LC3B-I and Sequestosome-1/p62 blots indicate signal saturation beyond the linear range determined for these proteins. Outcomes for LC3B-II were normalized to the Actin-β signal. Control, n=16 and COPD, n= 22. “**” denoted P < 0 . 01. Outcomes for the violin graphs were from non-parametric analyses; Wilcoxon matched pairs rank were used when comparing no-treatment and CQ, and Kruskall-Wallis rank test for comparisons between control vs COPD. Violin graphs boxplots show ± standard error and whiskers denote ± 95% CI .

Article Snippet: Briefly, HEK-293T cells were co-transfected with lentivirus construct encoding Cas9 and a sgRNA targeting exon 7 of ATG5 (LentiCRISPRv2- ATG5 ; Addgene, 99573 [ ]; deposited by Edward Campbell), pMDLg/pRRE (Addgene, 12251), pMD2.G (Addgene, 12259), and pRSV-REV (Addgene, 12253) (Packaging vectors deposited by Didier Trono) using Lipofectamine 3000 (ThermoFisher Scientific, L3000150).

Techniques: Isolation, Transduction, CRISPR, Construct